- Indication
- Endometriosis
- RAG rating
- Amber initiation
- Document type
- Decision document
- Place
- Hertfordshire and West Essex ICB
- Output type
- Pharmacy / Prescribing
Linzagolix
HERTFORDSHIRE AND WEST ESSEX AREA PRESCRIBING COMMITTEE (HWE APC)
Linzagolix for treating symptoms of endometriosis
AMBER INITIATION
Recommended for initiation by specialists, ongoing prescribing in primary care.
Name generic (trade) Linzagolix
What it is Non-peptide GnRH receptor antagonist
Indication Licensed for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis
Date decision last revised July 2025
NICE NICE TA 1067 recommended
HWE APC recommendation:
Linzagolix with hormonal add-back therapy is recommended in line with the recommendations of NICE TA1067 and can be used, within its marketing authorisation, as an option for treating symptoms of endometriosis in adults of reproductive age who have had medical (e.g. pain relief and hormonal treatment) or surgical treatment for endometriosis.
If people with the condition and their healthcare professional consider GnRh antagonists with add back hormonal therapy to a be suitable treatment, after discussing the advantages and disadvantages of all the options, the least expensive suitable treatment choice should be used.
AMBER INITIATION
Specialists’ responsibilities include:
At initiation
- provide information to the patient relating to the safe and effective use such as, but not limited to, ongoing BMD monitoring requirements and advice on contraception.
- advise patient on action to take if intolerance/significant side-effects develop prior to next follow up appointment and advise, if required, to contact initiating specialist for further treatment advice.
This information should be included in the clinic letter to primary care clinicians
During follow up care
- to arrange and review DEXA scan (recommended after one year of treatment) and ongoing BMD monitoring thereafter.
- to undertake initial and follow up reviews for efficacy and tolerance and advise primary care of the ongoing treatment plan.
During treatment, periodic check-ups must be carried out according to standard clinical practice.
Further information: for latest updates and more detailed information, including contra-indications, cautions and special warnings; please refer to summary of product characteristics SPC)
Linzagolix is a black Triangle drug ▼ report all suspected adverse reactions at Yellow Card | Making medicines and medical devices safer.
- Version number
- 1.0
- Developed by
- Pharmacy and Medicines Optimisation Team, Hertfordshire and West Essex (HWE) ICB with relevant HWE ICS stakeholders.
- Approved by
- Hertfordshire & West Essex Area Prescribing Committee
- Date approved / updated
- July 2025
- Review date
- This HWE APC recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available
- Superseded version
- NA